Evaluation of the Regulatory Required Post-Authorization Safety Study for Propacetamol: Nested Case-Control and...

Area of Science:

• Pharmacovigilance
• Real-world evidence studies
• Drug safety surveillance

Background:

• Propacetamol was withdrawn in Europe due to safety concerns.
• Regulatory authorities require post-marketing surveillance for drug safety.
• Investigating propacetamol's safety profile in South Korea is crucial.

Purpose of the Study:

• To assess the safety profile of propacetamol in South Korea.
• To investigate the risk of anaphylaxis, thrombosis, and Stevens-Johnson syndrome (SJS) associated with propacetamol.
• To provide real-world evidence for regulatory decision-making.

Main Methods:

• Nested case-control and case-time-control (CTC) analyses were conducted.
• Data from South Korea's claims database (2010-2019) were utilized.
• Risk-set sampling matched cases with up to 10 controls.

Main Results:

• The odds ratio (OR) for thrombosis in the nested case-control analysis was 1.60 (95% CI 0.71-3.62).
• In the CTC design, the OR for thrombosis was 0.56 (95% CI 0.09-3.47).
• ORs for anaphylaxis and SJS were inestimable due to limited propacetamol users.

Conclusions:

• Propacetamol was not associated with an increased risk of anaphylaxis, thrombosis, or SJS.
• Routinely collected clinical data provided reassuring real-world safety evidence.
• Findings support regulatory decision-making regarding propacetamol use.